Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Hageman

Showing results (251-260 of 271) with videos related to

Pageof 28
Sort By:
Mbio|May 23, 2025
Identification of a series of pyrrolo-pyrimidine-based SARS-CoV-2 Mac1 inhibitors that repress coronavirus replicationJessica J Pfannenstiel, Men Thi Hoai Duong, Daniel Cluff, et al.
Mbio|April 14, 2026
Correction for Pfannenstiel et al., "Identification of a series of pyrrolo-pyrimidine based SARS-CoV-2 Mac1 inhibitors that repress coronavirus replication"Jessica J Pfannenstiel, Men Thi Hoai Duong, Daniel Cluff, et al.
European Journal of Preventive Cardiology|October 8, 2022
Estimating individual lifetime risk of incident cardiovascular events in adults with Type 2 diabetes: an update and geographical calibration of the DIAbetes Lifetime perspective model (DIAL2)Helena Bleken Østergaard, Steven H J Hageman, Stephanie H Read, et al.
European Journal of Preventive Cardiology|February 9, 2023
Unexploited potential of risk factor treatment in patients with atherosclerotic cardiovascular diseaseTinka J van Trier, Marjolein Snaterse, Steven H J Hageman, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|October 10, 2025
Using SCORE2 with a risk chart or online calculator: Impact on model performance, treatment eligibility and cardiovascular disease preventionSteven H J Hageman, Stephen Kaptoge, Mari N Gynnild, et al.
Diabetes, Obesity & Metabolism|March 8, 2024
Lifetime and 10-year cardiovascular risk prediction in individuals with type 1 diabetes: The LIFE-T1D modelMarga A G Helmink, Steven H J Hageman, Björn Eliasson, et al.
Bioorganic & Medicinal Chemistry Letters|May 22, 2007
7-Oxo-4,7-dihydrothieno[3,2-b]pyridine-6-carboxamides: synthesis and biological activity of a new class of highly potent inhibitors of human cytomegalovirus DNA polymeraseScott D Larsen, Zhijun Zhang, Brian A DiPaolo, et al.
International Journal of Cardiology|September 7, 2024
Adding ethnicity to cardiovascular risk prediction: External validation and model updating of SCORE2 using data from the HELIUS population cohortJoshua A N van Apeldoorn, Steven H J Hageman, Ralf E Harskamp, et al.
Frontiers in Nutrition|December 5, 2022
Effects of a nutritional intervention on impaired behavior and cognitive function in an emphysematous murine model of COPD with endotoxin-induced lung inflammationCharlotte E Pelgrim, Ingrid van Ark, Ronja E van Berkum, et al.
European Journal of Preventive Cardiology|June 2, 2023
Improving 10-year cardiovascular risk prediction in apparently healthy people: flexible addition of risk modifiers on top of SCORE2Steven H J Hageman, Carmen Petitjaen, Lisa Pennells, et al.
Pageof 28

Showing results (251-260 of 271) with videos related to

Sort By:
Pageof 28
Mbio|May 23, 2025
Identification of a series of pyrrolo-pyrimidine-based SARS-CoV-2 Mac1 inhibitors that repress coronavirus replicationJessica J Pfannenstiel, Men Thi Hoai Duong, Daniel Cluff, et al.
Mbio|April 14, 2026
Correction for Pfannenstiel et al., "Identification of a series of pyrrolo-pyrimidine based SARS-CoV-2 Mac1 inhibitors that repress coronavirus replication"Jessica J Pfannenstiel, Men Thi Hoai Duong, Daniel Cluff, et al.
European Journal of Preventive Cardiology|October 8, 2022
Estimating individual lifetime risk of incident cardiovascular events in adults with Type 2 diabetes: an update and geographical calibration of the DIAbetes Lifetime perspective model (DIAL2)Helena Bleken Østergaard, Steven H J Hageman, Stephanie H Read, et al.
European Journal of Preventive Cardiology|February 9, 2023
Unexploited potential of risk factor treatment in patients with atherosclerotic cardiovascular diseaseTinka J van Trier, Marjolein Snaterse, Steven H J Hageman, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|October 10, 2025
Using SCORE2 with a risk chart or online calculator: Impact on model performance, treatment eligibility and cardiovascular disease preventionSteven H J Hageman, Stephen Kaptoge, Mari N Gynnild, et al.
Diabetes, Obesity & Metabolism|March 8, 2024
Lifetime and 10-year cardiovascular risk prediction in individuals with type 1 diabetes: The LIFE-T1D modelMarga A G Helmink, Steven H J Hageman, Björn Eliasson, et al.
Bioorganic & Medicinal Chemistry Letters|May 22, 2007
7-Oxo-4,7-dihydrothieno[3,2-b]pyridine-6-carboxamides: synthesis and biological activity of a new class of highly potent inhibitors of human cytomegalovirus DNA polymeraseScott D Larsen, Zhijun Zhang, Brian A DiPaolo, et al.
International Journal of Cardiology|September 7, 2024
Adding ethnicity to cardiovascular risk prediction: External validation and model updating of SCORE2 using data from the HELIUS population cohortJoshua A N van Apeldoorn, Steven H J Hageman, Ralf E Harskamp, et al.
Frontiers in Nutrition|December 5, 2022
Effects of a nutritional intervention on impaired behavior and cognitive function in an emphysematous murine model of COPD with endotoxin-induced lung inflammationCharlotte E Pelgrim, Ingrid van Ark, Ronja E van Berkum, et al.
European Journal of Preventive Cardiology|June 2, 2023
Improving 10-year cardiovascular risk prediction in apparently healthy people: flexible addition of risk modifiers on top of SCORE2Steven H J Hageman, Carmen Petitjaen, Lisa Pennells, et al.
Pageof 28